Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost

Martin KE, Yu J, Campbell HE, Abarca J, White TJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
21942301

Original Paper URL
http://www.amcp.org/JMCP/2011/October/12813/1033.html

Indexing Status
Subject indexing assigned by NLM

MeSH
Administration, Oral; Aged; Aged, 80 and over; Alendronate/advertisement & dosage/economics; Comparative Effectiveness Research; Diphosphonates/advertisement & dosage/economics; Drug Costs; Etidronic Acid/administration & dosage/analogues & derivatives/economics; Female; Follow-Up Studies; Fractures, Bone/economics/prevention & control; Humans; Insurance Claim Review; Longitudinal Studies; Male; Managed Care Programs; Medication Adherence; Middle Aged; Osteoporosis/drug therapy/economics; Regression Analysis; Retrospective Studies; Risedronate Sodium; United States

AccessionNumber
22012005641

Date bibliographic record published
25/07/2012